RxDoctor Payments Data

Ashee Amjad Amjad Waryam

Nurse Practitioner · Merced, CANPI 1760920391

Payments from drug & device makers

$7,038in general payments, 2019–2025

Across 365 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$833
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$704
  • Teva Pharmaceuticals USA, Inc.$664
  • Neurocrine Biosciences, Inc.$538
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,96399%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,038 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$24,426
Medicare patients
54
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$23,529
TrintellixVortioxetine Hydrobromide18$9,178
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$2,959
Sertraline Hcl147$2,229
Aripiprazole79$1,717
Lurasidone Hcl27$1,696
Quetiapine Fumarate135$1,490
Venlafaxine Hcl ErVenlafaxine Hcl90$1,430
Citalopram HbrCitalopram Hydrobromide19$1,368
Trazodone Hcl159$1,130
Bupropion XlBupropion Hcl79$1,052
Duloxetine Hcl76$806
Fluoxetine Hcl133$749
Hydroxyzine Hcl26$636
Escitalopram Oxalate109$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$833$23,52913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$150$9,17818 claims
Almatica Pharma LLCSertraline Hcl$34$2,229147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Merced

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →